BioCentury | Jan 4, 2016
Emerging Company Profile

Regrowing hearing

Acousia Therapeutics GmbH is developing small molecules to treat sensorineural hearing loss that could lead to better speech perception than a clinical-stage gene therapy that also aims to regenerate hair cells. With an investment from...
BC Week In Review | Feb 27, 2012
Clinical News

Autologous umbilical cord blood: Phase I started

Cord Blood Registry began an open-label, U.S. Phase I trial to evaluate a single dose of 6 million cells/kg intravenous autologous umbilical cord blood stem cells in 10 children ages 6 weeks to 18 months...
BC Week In Review | Feb 27, 2012
Clinical News

Autologous umbilical cord blood: Phase I/II started

Cord Blood Registry began a double-blind, placebo-controlled, U.S. Phase I/II trial to evaluate red-cell depleted, infused mononuclear cell enriched umbilical cord blood stem cells in 40 children ages 2-12 with cerebral palsy who do not...
Items per page:
1 - 3 of 3